Inflammatory mediator synthesis pathways

The term "inflammatory mediator synthesis pathways" collectively refers to the numerous cellular and biochemical routes by which pro- and anti-inflammatory molecules like cytokines, prostaglandins, leukotrienes, and others are generated during immune and inflammatory responses. Key enzymatic processes involve arachidonic acid metabolism by cyclooxygenase (COX) and lipoxygenase (LOX) to produce prostaglandins and leukotrienes, respectively[4][6][7]. Cytokine synthesis is regulated by transcription factors such as NF-κB, STAT, and HIF-1α, which promote rapid cellular signaling in response to injury or infection[5]. While pharmaceutical interventions frequently target specific enzymes, receptors, or mediators within these pathways, the full set of pathways itself does not constitute a druggable target, but rather describes an entire process involved in disease physiology and therapeutic intervention[6][5][4].

Other names

Inflammatory mediator pathwaysInflammatory response pathwaysBiochemical inflammatory mediator synthesis

Inhibition of enzyme pathways (e.g., COX inhibitors block prostaglandin synthesis); Inhibition/blockade of mediators or their receptors (e.g., monoclonal antibodies against cytokines); Modulation of signal transduction (e.g., NF-κB inhibition)